Details About Generic Salt ::  Linezoli

Main Medicine Class:: Anti-infective, Antibiotic   

(lin-EH-zoe-lid)

Zyvox

Tablets: 400 mg (sodium content is 1.95 mg/400 mg tablet [0.1 mEq/tablet]), Tablets: 600 mg (sodium content is 2.92 mg/600 mg tablet [0.1 mEq/tablet]), Powder for reconstitution: 100 mg/5 mL (sodium content is 8.52 mg/5 mL [0.5 mEq/5 mL]), Injection: 2 mg/mL (sodium content is 0.38 mg/mL [5 mEq/300 mL bag, 3.3 mEq/200 mL bag, 1.7 mEq/100 mL bag])

Class: Anti-infective, Antibiotic

 

Drugs Class ::

 Action Prevents the formation of a functional 70S initiation complex, which is essential to the bacterial translation process.

Indications for Drugs ::

 Indications Treatment of vancomycin-resistant Enterococcus faecium infections; treatment of nosocomial pneumonia, complicated and uncomplicated skin and skin structure infections, and community-acquired pneumonia due to susceptible strains of specific organisms.

Drug Dose ::

 Route/Dosage

Vancomycin-Resistant: E. faecium Infections, Including Concomitant Bacteremia Adults: PO or IV 600 mg q 12 hr for 14 to 28 days.

Nosocomial Pneumonia, Complicated Skin And Skin Structure Infections, Community-Acquired Pneumonia, Including Concomitant Bacteremia Adults: PO or IV 600 mg q 12 hr for 10 to 14 days.

Uncomplicated Skin And Skin Structure Infections Adults: PO 400 mg q 12 hr for 10 to 14 days.

Contraindication ::

 Contraindications Standard considerations.

Drug Precautions ::

 Precautions

Pregnancy: Category C. Lactation: Excreted in breast milk. Children: Safety and efficacy not established. Pseudomembranous colitis: Consider pseudomembranous colitis in patients in whom diarrhea develops. Myelosuppression: Because myelosuppression has been reported, monitor CBC weekly in patients receiving linezolid.

PATIENT CARE CONSIDERATIONS

Drug Side Effects ::

 Adverse Reactions

CARDIOVASCULAR: Hypertension. CNS: Headache; dizziness; insomnia. DERMATOLOGIC: Rash. EENT: Taste alteration; tongue discoloration; oral moniliasis. GI: Diarrhea; nausea; vomiting; constipation; dyspepsia; abdominal pain. GU: Vaginal moniliasis. HEMATOLOGIC: Thrombocytopenia. HEPATIC: Abnormal LFTs. OTHER: Fungal infection; fever; pruritus.

Drug Mode of Action ::  

 Action Prevents the formation of a functional 70S initiation complex, which is essential to the bacterial translation process.

Drug Interactions ::

 Interactions Adrenergic Agents (eg, dopamine, epinephrine): Effects may be enhanced by linezolid.

Serotonergic Agents (eg, fluoxetine): Possible increased risk of serotonin syndrome.

Drug Assesment ::

 Assessment/Interventions

• Obtain patient history, including drug history and any known allergies. Note history of hypertension, hepatic impairment, myelosuppression or concurrent use of bone marrow suppressive therapy, or phenylketonuria.
• Review results of culture and sensitivity testing as available.
• Ensure that CBC is determined weekly during therapy with linezolid.
• Ensure that patient's diet contains no food with high tyramine content.
• Monitor for signs of infection, especially fever, and for positive response to antibiotic therapy.
• Monitor patient for signs of allergic reaction. Discontinue therapy and immediately notify health care provider if noted.
• Monitor patient for GI, CNS, and general body side effects. Report to health care provider if noted and significant.

Drug Storage/Management ::

 Administration/Storage

• Do not administer suspension to patient with phenylketonuria without first discussing with health care provider.
• Administer prescribed dose q 12 hr.
• No dose adjustment is needed when switching from IV to oral tablets or suspension.
• Administer tablets and suspension without regard to meals.
• Gently mix suspension by inverting bottle 3 to 5 times before each dose. Do not shake suspension.
• Use suspension for adults who have difficulty swallowing.

IV Administration

• Keep infusion bag in protective overwrap until ready to administer.
• Before administering, check IV bag for minute leaks by firmly squeezing bag, and visually inspect for particulate matter. Do not use if either is noted.
• Solution may exhibit a yellow color, which is normal and does not affect potency.
• Administer IV infusion over 30 to 120 min.
• Do not use IV infusion bag in series connections nor add any other medications to bag.
• If other drugs are being administered through same IV line, flush line before and after infusion of linezolid with 5% Dextrose Injection, 0.9% Sodium Chloride Injection, or Lactated Ringer's Injection.
• Store tablets, suspension, and IV solution at controlled room temperature. Protect infusion bags from freezing. Protect from light. Keep bottles tightly closed. Discard any unused suspension after 21 days.

Drug Notes ::

 Patient/Family Education

• Explain name, dose, action, and potential side effects of drug.
• Review dosing schedule and prescribed length of therapy with patient. Advise patient that dose and duration of therapy are dependent on site and cause of infection.
• Advise patient that medication may be taken without regard to meals.
• Instruct patient to complete entire course of therapy, even if symptoms of infection have disappeared.
• Instruct patient to avoid foods with high tyramine content. Review common foods known to have high tyramine content (eg, aged cheeses, soy sauce, fermented or air-dried meats, sauerkraut, tap beers, red wines).
• Advise patient that diarrhea, headache, and nausea are the most common side effects, and to inform health care provider if these symptoms occur and are intolerable.
• Advise patient to discontinue therapy and contact health care provider immediately if skin rash, hives, itching, or shortness of breath occurs.
• Advise patient to report the following signs of superinfection to health care provider: black “furry” tongue, white patches in mouth, foul-smelling stools, vaginal itching or discharge.
• Warn patient that diarrhea containing blood or pus may be a sign of a serious disorder and to seek medical care if noted and not to treat at home.
• Caution patient to not take any otc cold products or decongestants containing ephedrine, pseudoephedrine, or phenylpropranolamine.
• Instruct patient to not take any prescription or otc medications or dietary supplements unless advised to do so by health care provider.
• Advise patient that follow-up examinations and lab tests may be required to monitor therapy and to be sure and keep appointments.

–>

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.